Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

FuturHealth vs Trimrose

FuturHealth
Graded #215

Higher grade

vs+10.199999999999996
Trimrose
Graded #440

Lower grade

The verdict

FuturHealth takes it — 65.6/100 to 55.4/100.

FuturHealth grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. FuturHealth Inc. is a San Diego-based telehealth weight management brand offering brand-name Ozempic, Wegovy (injection AND oral pill), Mounjaro, Zepbound, and Foundayo (orforglipron oral pill, added

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueFuturHealth +20
60
40
Dose & formulationFuturHealth +17
81
64
Clinical oversightTrimrose +1
67
68
Labs & monitoringFuturHealth +9
61
52
FulfillmentFuturHealth +5
62
57
Contract termsEven
55
55
FuturHealth · left barTrimrose · right bar

The numbers

MetricFuturHealthTrimrose
WeighScore65.6/10055.4/100
GradeCC
Scorecard rank#215#440
Semaglutide$199/mo (compounded)Not disclosed
TirzepatideNot disclosedNot disclosed
CoverageCoverage not publishedCoverage not published
Brand-name accessYesYes
Oral / sublingualYesYes
FuturHealth

Graded #215 · C

Strengths

  • LegitScript Certified and HITRUST Certified
  • Brand-name and oral GLP-1s on one platform: Wegovy injection and pill, Zepbound, Mounjaro, Ozempic, and Foundayo
  • Early direct-to-consumer access to Foundayo (orforglipron), the new oral non-peptide GLP-1
  • Bundled registered-dietitian nutrition guidance — uncommon among pure-Rx telehealths

Where it loses points

  • Active lawsuit (Wilson v. FuturHealth) alleging unauthorized access to G-Plans subscriber data
  • BBB complaints describe recurring charges without medication received — confirm cancellation flow first
  • Pharmacy partners described only as 'licensed, U.S.-based' with no specific 503A/503B names
  • Pricing not shown until after the qualification questionnaire or portal login
  • Front-end brand built on SteadyMD and OpenLoop infrastructure, not a first-party prescriber
Trimrose

Graded #440 · C

Strengths

  • Free, no-cost, no-obligation online eligibility quiz before any commitment
  • Offers a choice of a weekly compounded GLP-1 injection or a daily oral option
  • Fully online — assessment, provider review, and home delivery with ongoing support

Where it loses points

  • Runs on the CareValidate white-label platform and isn't the medical provider itself — a support@carevalidate.com address is exposed on the site
  • Pricing isn't shown publicly; the cost and the specific compounded molecule appear only after you complete the eligibility quiz
  • The states served, pharmacy partner and any LegitScript/503A certification aren't disclosed on the public site
  • Markets 'up to 22.5% of body weight' — a trial figure for branded tirzepatide, not a guaranteed or compounded-specific outcome
  • Compounded GLP-1s are not FDA-reviewed or approved — a different evidence and regulatory tier than brand-name

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard